80 related articles for article (PubMed ID: 35266034)
41. Effects of Soluble Tumor Necrosis Factor (TNF) on Antibody-Dependent Cellular Cytotoxicity of Therapeutic anti-TNF-α Antibody.
Hirosaki H; Maeda Y; Shimojima M; Maeda K; Iwata H; Takeyoshi M
Immunol Invest; 2019 Jul; 48(5):441-450. PubMed ID: 30569777
[TBL] [Abstract][Full Text] [Related]
42. Targeting FcRn to Generate Antibody-Based Therapeutics.
Ward ES; Ober RJ
Trends Pharmacol Sci; 2018 Oct; 39(10):892-904. PubMed ID: 30143244
[TBL] [Abstract][Full Text] [Related]
43. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
44. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.
Liu L
Protein Cell; 2018 Jan; 9(1):15-32. PubMed ID: 28421387
[TBL] [Abstract][Full Text] [Related]
46. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
[TBL] [Abstract][Full Text] [Related]
47. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.
Ternant D; Arnoult C; Pugnière M; Dhommée C; Drocourt D; Perouzel E; Passot C; Baroukh N; Mulleman D; Tiraby G; Watier H; Paintaud G; Gouilleux-Gruart V
J Immunol; 2016 Jan; 196(2):607-13. PubMed ID: 26685205
[TBL] [Abstract][Full Text] [Related]
48. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies.
Laurent L; Anquetil F; Clavel C; Ndongo-Thiam N; Offer G; Miossec P; Pasquali JL; Sebbag M; Serre G
Ann Rheum Dis; 2015 Jul; 74(7):1425-31. PubMed ID: 24618262
[TBL] [Abstract][Full Text] [Related]
49. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.
Lv Q; Yin Y; Li X; Shan G; Wu X; Liang D; Li Y; Zhang X
PLoS One; 2014; 9(2):e89442. PubMed ID: 24586782
[TBL] [Abstract][Full Text] [Related]
50. Rheumatoid factors: clinical applications.
Ingegnoli F; Castelli R; Gualtierotti R
Dis Markers; 2013; 35(6):727-34. PubMed ID: 24324289
[TBL] [Abstract][Full Text] [Related]
51. A rheumatoid factor paradox: inhibition of rituximab effector function.
Jones JD; Shyu I; Newkirk MM; Rigby WF
Arthritis Res Ther; 2013 Jan; 15(1):R20. PubMed ID: 23351360
[TBL] [Abstract][Full Text] [Related]
52. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
Takeuchi T; Miyasaka N; Tatsuki Y; Yano T; Yoshinari T; Abe T; Koike T
Ann Rheum Dis; 2011 Jul; 70(7):1208-15. PubMed ID: 21478189
[TBL] [Abstract][Full Text] [Related]
53. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
54. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Aletaha D; Neogi T; Silman AJ; Funovits J; Felson DT; Bingham CO; Birnbaum NS; Burmester GR; Bykerk VP; Cohen MD; Combe B; Costenbader KH; Dougados M; Emery P; Ferraccioli G; Hazes JM; Hobbs K; Huizinga TW; Kavanaugh A; Kay J; Kvien TK; Laing T; Mease P; Ménard HA; Moreland LW; Naden RL; Pincus T; Smolen JS; Stanislawska-Biernat E; Symmons D; Tak PP; Upchurch KS; Vencovský J; Wolfe F; Hawker G
Arthritis Rheum; 2010 Sep; 62(9):2569-81. PubMed ID: 20872595
[TBL] [Abstract][Full Text] [Related]
55. Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.
Onishi S; Yoshio T; Nagashima T; Minota S
Mod Rheumatol; 2010 Oct; 20(5):528-30. PubMed ID: 20458607
[No Abstract] [Full Text] [Related]
56. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
57. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
Bourne T; Fossati G; Nesbitt A
BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
[TBL] [Abstract][Full Text] [Related]
58. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
Potter C; Hyrich KL; Tracey A; Lunt M; Plant D; Symmons DP; Thomson W; Worthington J; Emery P; Morgan AW; Wilson AG; Isaacs J; Barton A;
Ann Rheum Dis; 2009 Jan; 68(1):69-74. PubMed ID: 18375541
[TBL] [Abstract][Full Text] [Related]
59. FcRn: the neonatal Fc receptor comes of age.
Roopenian DC; Akilesh S
Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
[TBL] [Abstract][Full Text] [Related]
60. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
